FMP
Organovo Holdings, Inc.
ONVO
NASDAQ
Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. The company was incorporated in 2007 and is headquartered in Solana Beach, California.
0.361 USD
-0.0391 (-10.83%)
About
ceo
Mr. Keith E. Murphy
sector
Healthcare
industry
Biotechnology
website
https://www.organovo.comexchange
NASDAQ
Description
Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. The company was incorporated in 2007 and is headquartered in Solana Beach, California.
CIK
0001497253
ISIN
US68620A2033
CUSIP
68620A203
Address
11555 Sorrento Valley Road
Phone
858 224 1000
Country
US
Employee
12
IPO Date
Feb 14, 2012
Key Executives
